首页> 外文期刊>Surgical oncology clinics of North America >Nonsurgical management of Barrett's esophagus with high-grade dysplasia.
【24h】

Nonsurgical management of Barrett's esophagus with high-grade dysplasia.

机译:Barrett食管高度不典型增生的非手术治疗。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Endoscopic management options for BE with high-grade dysplasia consist of either surveillance methods or endoscopic mucosal ablative therapies. Intensive surveillance once a person is diagnosed with high-grade dysplasia may avoid an unneeded esophagectomy because it appears that most patients with high-grade dysplasia may not progress to esophageal adenocarcinoma. Only a single study has been presented that demonstrates that this approach does not lead to missed opportunities for intervention before progression to advanced stage disease [20]. This study excluded patients with cancer detected within 1 year of diagnosis of high-grade dysplasia; thus, patients who wish to proceed with an observation approach should be aware that the rate of missed esophageal adenocarcinomas ranges from 38% to 73%. The ability to observe a patient with high-grade dysplasia, however, does have appeal because a number of these patients appear to lose the high-grade dysplasia over time. The other endoscopic management option for Barrett's esophagus with high-grade dysplasia is endoscopic mucosal ablative therapies. These include the KTP:YAG laser, the Nd:YAG laser, photodynamic therapy, and endoscopic mucosal resection. All ablative therapies are used in combination with control of gastroesophageal reflux. This allows the esophageal tissue to heal in an environment that is conducive to squamous mucosa. Although most are relatively small series with short durations of observation, they all have shown some promise in treating BE with high-grade dysplasia. These approaches have the advantage of eliminating the problem. The patient who is being observed must live with the thought of developing cancer. Patients who undergo successful ablation are returned to a normal life. The combination of therapies such as EMR with PDT may be the most promising approach to BE with high-grade dysplasia; however, the long-term effects of ablative therapy are not known and continued surveillance is still advised for this group of patients. The choice of a nonsurgical approach for the management of BE with high-grade dysplasia is ultimately up to the individual patient. All patients must be carefully informed of the treatment effects, possible outcomes, and the surgical alternative. Most patients who select nonsurgical approaches are either elderly or are not good surgical candidates. The choice is often affected by local expertise, as surgical procedures should be performed in centers with surgeons expert in esophagectomy. Nonsurgical approaches should also be performed by physicians who are familiar with their application. Future advances in nonsurgical techniques such as new photosensitizers in PDT and improvements in diagnostic techniques may allow patients a greater opportunity to preserve their esophagus.
机译:伴有高度不典型增生的BE的内镜治疗选择包括监视方法或内镜黏膜消融治疗。一旦被诊断为高度不典型增生,就应进行强化监护,从而避免不必要的食管切除术,因为似乎大多数高度不典型增生的患者可能不会发展为食管腺癌。仅提出了一项研究,证明该方法不会导致进展为晚期疾病[20]。该研究排除了在诊断为高度不典型增生的一年内发现的癌症患者;因此,希望继续观察的患者应注意,食管腺癌漏诊率在38%至73%之间。但是,观察具有高度不典型增生的患者的能力确实具有吸引力,因为随着时间的流逝,这些患者中的许多人似乎丧失了高度不典型的增生。患有高度不典型增生的巴雷特食管的另一种内窥镜治疗方法是内窥镜黏膜消融治疗。这些包括KTP:YAG激光,Nd:YAG激光,光动力疗法和内窥镜黏膜切除术。所有消融疗法均与控制胃食管反流结合使用。这允许食道组织在有利于鳞状粘膜的环境中愈合。尽管大多数是相对较小的系列,观察时间很短,但它们都显示出在治疗高度发育异常的BE中有希望。这些方法具有消除问题的优点。被观察的患者必须忍受罹患癌症的念头。消融成功的患者将恢复正常生活。 EMR和PDT等疗法的结合可能是高度发展性异型增生的最有前途的方法。然而,消融治疗的长期效果尚不清楚,因此仍建议对该组患者进行持续监测。对于非典型增生的BE,非手术治疗的选择最终取决于每个患者。必须仔细告知所有患者治疗效果,可能的结果以及手术选择。选择非手术方法的大多数患者都是年老或不是良好的手术候选人。选择通常受当地专业知识的影响,因为手术过程应在食管切除术的外科医生中心进行。非手术方法也应由熟悉其应用的医师进行。非手术技术的未来进展,例如PDT中的新型光敏剂以及诊断技术的改进,可能使患者有更大的机会来保存其食道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号